Owkin has announced a new partnership with AstraZeneca to develop an AI-powered tool to pre-screen for gBRCA mutations in breast cancer directly from digitized pathology slides. This collaboration aims to significantly accelerate and expand access to gBRCA testing, allowing more patients to benefit from tailored care.
Company Information
Company
Owkin
Location
Paris, Ile-de-France, France
About
Owkin is a TechBio company that combines the best of human and artificial intelligence to find the right treatment for every patient. They are on a mission to understand complex biology, derive new multimodal biomarkers through AI, identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies.